Orange County Business Journal reported that Michael McGarrity has directed Irvine-based MDxHealth since taking over leadership starting in 2019. Michael McGarrity brought a robust professional background to the organization, holding more than 25 years of healthcare industry experience accrued across multiple corporate environments. Before stepping into the top role at MDxHealth, Michael McGarrity built a long career that included serving in previous leadership roles at Stryker. Furthermore, Michael McGarrity served in the executive capacity as the chief executive officer of Sterilis Medical before making the permanent move to lead MDxHealth based in Irvine.

During the years that Michael McGarrity managed the firm, MDxHealth experienced measurable financial growth within the competitive healthcare sector. When evaluating the commercial progress of MDxHealth since the beginning of the leadership term, financial disclosures show that annual sales grew from about $11.8M in 2019. This upward financial movement persisted across the operational periods, leading to significantly higher annual totals. By the time fiscal metrics were recorded for later periods, revenue climbed 20% to reach $107.9M in 2025. This notable performance highlights the expanding scale of commercial operations maintained by the Irvine company.

Alongside financial expansion, MDxHealth actively pursued academic partnerships and corporate acquisitions to broaden its operational scope, market presence, and scientific portfolio. In the realm of scientific research, MDxHealth published initial research resulting directly from a University of Oxford collaboration. This published study represents a key milestone for the firm's ongoing scientific endeavors. On the corporate acquisition front, MDxHealth completed a major transaction by formally acquiring Exosome Diagnostics in September 2025, successfully bringing the external diagnostic capabilities and assets under the corporate umbrella of MDxHealth.

The combination of these published scientific findings and strategic corporate acquisitions forms a core part of the overall business strategy overseen by Michael McGarrity at MDxHealth. Commenting on the strategic significance of the scientific work produced through the academic partnership, the executive highlighted the path toward clinical integration and broader medical acceptance. "This publication supports our advancement of GPS with regard to guideline development, payer coverage and physician adoption," Michael McGarrity told Orange County Business Journal. This framework illustrates how specific research milestones directly contribute to the broader clinical acceptance, insurance coverage, and practical utilization of diagnostic tools within the wider medical community.